Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

Liraglutide

metabolicweight-lossdiabetes
Regulatory status — FDA-approved for indicated use

Liraglutide is a GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda) [1] [2]. It reduces body weight and improves cardiometabolic outcomes in adults with obesity and metabolic syndrome [3] [4], and has shown efficacy in polycystic ovary syndrome [7].

Evidence coverage

65/72 claims verified by independent fact-checker.

Pepteligence regenerates entries quarterly and when new high-tier evidence appears.

Quick facts

Half-life
~13h [1]
Typical dose
0.6–3.0 mg/day SC [2]
Route
subcutaneous
Frequency
once daily [2]
Cycle length
ongoing [2]
Evidence strength
Phase III RCTs

Suggested labs for this peptide class — educational reference only; not medical advice.

Official prescribing information

The following sections are reproduced from the FDA-approved prescribing information. This is the authoritative clinical record — not editorial content.

Approved use(s)

SAXENDA is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Limitations of Use Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. Adults wi…

Dosing & administration

Prior to initiation of SAXENDA, train patients on proper injection technique. Refer to the accompanying Instructions for Use for complete administration instructions with illustrations. Inspect SAXENDA visually prior to each injection. Only use if solution is clear, colorless, and contains no partic…

Warnings & precautions

Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and/or carcinomas) at clinically relevant exposures in both genders of rats and mice. Malignant thyroid C-cell carcinomas were detected in rats and mice. It is unknown whether SAXENDA will cause thyroi…

Contraindications

SAXENDA is contraindicated in: 5.1. Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions ( 5.8 )]. Patients with a serious hypersensitivity reaction to liraglutide or to any…

Drug interactions

SAXENDA causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, liraglutide did not affect the absorption of the tested orally administered medications to any clinically relevant degre…

Adverse reactions

The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-Cell Tumors Acute Pancreatitis Acute Gallbladder Disease Risk for Hypoglycemia with Concomitant Use of Anti-Diabetic Therapy Heart Rate Increase Acute Kidney Injury Due to Volum…

Source: FDA-approved prescribing information for Saxenda, last updated February 25, 2026. View original at DailyMed →

TL;DR

  • Half-life: ~13h — dosed once daily.
  • Administered via subcutaneous.
  • Evidence base: randomised controlled trials.
  • Primary goals: metabolic, weight-loss, diabetes.
EVIDENCE HIERARCHYRCTsObservationalAnimal studiesAnecdotal

Randomised controlled trials

How we evaluate evidence →

How it works

GHRH analogues stimulate pulsatile GH release from the pituitary, elevating IGF-1 and promoting fat oxidation.

Liraglutide is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor, a G-protein-coupled receptor expressed in pancreatic beta cells, the gastrointestinal tract, and the central nervous system [11]. Through GLP-1 receptor signaling, liraglutide promotes satiety and reduces appetite, leading to decreased caloric intake and weight loss [11] [12]. The compound enhances insulin secretion in response to elevated blood glucose and inhibits glucagon release, thereby improving glycemic control in type 2 diabetes [11]. Beyond glucose homeostasis, liraglutide modulates the Nrf2/HO-1 signaling pathway to enhance antioxidant and anti-inflammatory effects [12]. In preclinical models, liraglutide reduces systemic inflammation in high-fat-diet-induced obese mice [13] and modulates zinc release to improve mitochondrial function in insulin-resistant cardiomyocytes [14]. Liraglutide also activates cyclooxygenase-2 signaling to mediate adipose lipolytic activity, contributing to fat mobilization [15]. In high-carbohydrate-induced metabolic syndrome rat models, liraglutide treatment alleviates cardiac dysfunction through improvements in electrical and intracellular calcium abnormalities [16]. These pleiotropic effects on insulin secretion, appetite regulation, inflammation, and mitochondrial function underpin liraglutide's broad cardiometabolic benefits.

What the research says

Research summary content coming soon. Check the references section for indexed studies.

100%50%25%0%00h1t½13h2t½26h3t½39h4t½52h
Approximate plasma concentration over 4 half-lives (13h × 4 = 52h)

Protocol lifecycle

BeforeDuringAfter

Before — Pre-cycle readiness

Readiness checklist

Pre-treatment screening
  • Confirm absence of personal or family history of medullary thyroid carcinoma [1]
  • Confirm absence of multiple endocrine neoplasia syndrome type 2 [1]
  • Obtain baseline HbA1c, fasting glucose, and lipid panel [1]
  • Assess renal function (eGFR, serum creatinine) [1]
  • Review history of pancreatitis or gallbladder disease [1]
  • Baseline ophthalmologic assessment if diabetic retinopathy present [9]
Dosing and titration
  • Start at 0.6 mg subcutaneous once daily [2]
  • Increase by 0.6 mg weekly to target dose of 1.8–3.0 mg daily [2]
  • Inject subcutaneously in abdomen, thigh, or upper arm [2]
  • Rotate injection sites to reduce lipodystrophy risk [2]
Monitoring during treatment
  • Assess HbA1c and fasting glucose at 3–6 month intervals [1]
  • Monitor for gastrointestinal side effects (nausea, vomiting, diarrhea) [1]
  • Evaluate for pancreatitis symptoms (acute abdominal pain) [1]
  • Screen for visual symptoms or eye pain (NAION risk) [5]
  • Assess for cutaneous adverse events (rash, alopecia) [6]
  • Recheck renal function annually [10]
  • Screen for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1]
  • Obtain baseline HbA1c and fasting glucose [1]
  • Assess renal function and baseline lipid panel [1]
  • Evaluate for history of pancreatitis or gallbladder disease [1]

During — Active protocol

Protocol notice — The following describes common protocols reported in research and community sources. This is not medical advice. Dosing, frequency, and duration should be determined with a licensed physician familiar with peptide research.
  • Titrate dose gradually from 0.6 mg to target dose of 1.8–3.0 mg daily over 4–5 weeks [2]
  • Monitor for gastrointestinal side effects, particularly nausea and vomiting [1]
  • Monitor HbA1c and fasting glucose at 3–6 month intervals [1]
  • Assess for signs of pancreatitis (abdominal pain, elevated pancreatic enzymes) [1]
  • Monitor for visual symptoms or eye pain suggestive of NAION [5]
  • Evaluate for cutaneous adverse events including rash or hair loss [6]

After — Post-cycle

  • Monitor renal function and proteinuria for 3–6 months post-discontinuation [10]
  • Reassess glycemic control and weight if transitioning to alternative therapy [10]

Stacks it appears in

Liraglutide is typically used as a standalone compound. Stack data coming soon.

Related peptides

Other compounds indexed on Pepteligence that share research tags with Liraglutide. Educational context only.

Tirzepatide

Tier 1
metabolicweight-loss

Semaglutide

Tier 1
metabolicweight-loss

MOTS-c

Tier 3
metabolic

Tesamorelin

Tier 1
metabolic

Safety

Common side effects

  • ·Nausea [1]
  • ·Vomiting [1]
  • ·Diarrhea [1]
  • ·Constipation [1]
  • ·Headache [1]
  • ·Hypoglycemia (when combined with insulin or sulfonylureas) [1]

Rare side effects

  • ·Non-arteritic anterior ischemic optic neuropathy (NAION) [5]
  • ·Acute pancreatitis [1]
  • ·Gallbladder disease [1]
Safety notice — Serious / theoretical risks:
  • Anaphylaxis or severe hypersensitivity reaction [1]
  • Medullary thyroid carcinoma (contraindicated in personal/family history) [1]
  • Multiple endocrine neoplasia syndrome type 2 (contraindicated) [1]
  • Acute kidney injury [1]
  • Severe dehydration [1]

Contraindications

  • ·Personal or family history of medullary thyroid carcinoma [1]
  • ·Multiple endocrine neoplasia syndrome type 2 [1]
  • ·Known hypersensitivity to liraglutide or any component of the formulation [1]

Community experiences

Community content — User-submitted experiences are self-reported and have not been verified. They do not constitute medical advice. Pepteligence aggregates community data under Section 230 protections.

No community experiences yet for Liraglutide. Be the first to share yours.

Share your experience →

Have you tried Liraglutide?

Share your protocol and outcome to help build the community dataset.

Share your experience →

Liraglutide — at a glance

PropertyLiraglutide—
Half-life~13h—
Routesubcutaneous—
Typical dose0.6–3.0 mg/day SC—
MechanismLiraglutide is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor, a G-protein-coupled receptor expressed in pancreatic beta cells, the gastrointestinal tract, and the central nervous system. Through GLP-1 receptor signaling, liraglutide promotes satiety and reduces appetite, leading to decreased caloric intake and weight loss. The compound enhances insulin secretion in response to elevated blood glucose and inhibits glucagon release, thereby improving glycemic control in type 2 diabetes. Beyond glucose homeostasis, liraglutide modulates the Nrf2/HO-1 signaling pathway to enhance antioxidant and anti-inflammatory effects. In preclinical models, liraglutide reduces systemic inflammation in high-fat-diet-induced obese mice and modulates zinc release to improve mitochondrial function in insulin-resistant cardiomyocytes. Liraglutide also activates cyclooxygenase-2 signaling to mediate adipose lipolytic activity, contributing to fat mobilization. In high-carbohydrate-induced metabolic syndrome rat models, liraglutide treatment alleviates cardiac dysfunction through improvements in electrical and intracellular calcium abnormalities. These pleiotropic effects on insulin secretion, appetite regulation, inflammation, and mitochondrial function underpin liraglutide's broad cardiometabolic benefits.—
Evidence strengthrctanecdotal
Primary goalmetabolic—

Frequently asked questions

References

  1. [1]

    VICTOZA (liraglutide) injection, for subcutaneous use — Prescribing Information

    U.S. Food and Drug Administration

    FDA/DailyMed · 2025

    View on PubMed →
  2. [2]

    SAXENDA (liraglutide) injection, for subcutaneous use — Prescribing Information

    U.S. Food and Drug Administration

    FDA/DailyMed · 2026

    View on PubMed →
  3. [3]

    GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis

    Sawicka-Gutaj N, Gruszczyński D, Nijakowski K, et al.

    International Journal of Obesity · 2026 · PMID 42034831

    View on PubMed →
  4. [4]

    Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome

    Freitas FPC, Rodrigues CEM

    Scientific Reports · 2023 · PMID 37567946

    View on PubMed →
  5. [5]

    Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide

    Vilsbøll T, Arun Kumar Dikshit, Aiello LP, et al.

    The British Journal of Ophthalmology · 2026 · PMID 42049287

    View on PubMed →
  6. [6]

    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in dermatology: cutaneous adverse events and emerging efficacy in inflammatory skin diseases

    Ho MJ, Liew CF, Tan NS, et al.

    Expert Review of Clinical Immunology · 2026 · PMID 42043978

    View on PubMed →
  7. [7]

    Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis

    Lu YT, Chang PH, Chen HJ, et al.

    Diabetes, Obesity & Metabolism · 2026 · PMID 41508932

    View on PubMed →
  8. [8]

    Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome

    Ou T, Wang W, Yong H, et al.

    Alternative Therapies in Health and Medicine · 2022 · PMID 35751892

    View on PubMed →
  9. [9]

    Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy

    Shah J, Makwana B, Panchal K, et al.

    American Journal of Ophthalmology · 2026 · PMID 42025665

    View on PubMed →
  10. [10]

    Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study

    Takashima S, Terui K, Yamada F, et al.

    Diabetology International · 2026 · PMID 42078492

    View on PubMed →
  11. [11]

    The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review

    Dinkov B, Pendicheva-Duhlenska D

    Biomedicines · 2026 · PMID 42072347

    View on PubMed →
  12. [12]

    The Effect of Liraglutide on the Hypolipidemic, Anti-Inflammatory, and Antioxidant Properties of Atorvastatin Mediated via the Nrf2/HO-1 Signaling Pathway: In Vivo and In Silico Validation

    Kamar SA, Magdy YM, Abuamara TMM, et al.

    Pharmaceutics · 2026 · PMID 42076140

    View on PubMed →
  13. [13]

    Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice

    Sha S, Liu X, Zhao R, et al.

    Endocrine · 2019 · PMID 31542859

    View on PubMed →
  14. [14]

    Liraglutide Modulates Zinc Release and Improves Mitochondrial Function in Insulin-Resistant Senescent Cardiomyocytes

    Hosseinpourshirazi F, Mendes UD, Aksoy ZB, et al.

    Cardiovascular Toxicology · 2026 · PMID 41604031

    View on PubMed →
  15. [15]

    Activation of cyclooxygenase-2 signaling mediates liraglutide-induced adipose lipolytic activity

    Li J, Wu H, Ma W, et al.

    European Journal of Pharmacology · 2025 · PMID 40935112

    View on PubMed →
  16. [16]

    Glucagon-like peptide-1 receptor agonist treatment of high carbohydrate intake-induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction

    Durak A, Akkus E, Canpolat AG, et al.

    Clinical and Experimental Pharmacology & Physiology · 2022 · PMID 34519087

    View on PubMed →
  17. [?]

    The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review

    Corcoran E, Kettlety M, Mogul U, et al.

    Molecular and Cellular Neurosciences · 2026 · PMID 42014236

    View on PubMed →